— Know what they know.
Not Investment Advice
Also trades as: CBTE (OTC) · $vol 0M

INTI OTC

Inhibitor Therapeutics, Inc.
1W: -2.0% 1M: +10.1% 3M: +24.8% YTD: +109.0% 1Y: +96.0% 3Y: +188.2% 5Y: -69.4%
$0.10
-0.00 (-2.00%)
 
Weekly Expected Move ±41.2%
$0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 59 · $16.9M mcap · 78M float · 0.026% daily turnover · Short 88% of daily vol

Balance Sheet Trends

Total Assets
$3M -55.9% ▼
5Y CAGR: +80.3%
Total Liabilities
$4M +2.5% ▲
5Y CAGR: +1.7%
Shareholders Equity
-$1M -165.1% ▼
Cash & Investments
$2M -57.6% ▼
5Y CAGR: +99.6%
Total Debt
$62K +0.0% ▲
5Y CAGR: -8.6%
Net Debt
-$2M +58.7% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$31K$12M$9M$6M$2M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$31K$12M$9M$6M$2M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$0$109K$88K$72K
Total Current Assets$59K$12M$9M$6M$2M
Property, Plant & Equip.$0$0$0$0$64K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$0$0
Total Non-Current Assets$0$0$0$0$64K
Total Assets$59K$12M$9M$6M$3M
— Liabilities —
Accounts Payable$280K$145K$34K$16K$52K
Short-Term Debt$231K$411K$0$0$25K
Deferred Revenue$116K$3M$0$0$3M
Other Current Liabilities$0$123K$0$0-$2M
Total Current Liabilities$680K$679K$665K$710K$766K
Long-Term Debt$0$0$0$0$37K
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$3M$3M$3M$3M$3M
Total Liabilities$4M$4M$4M$4M$4M
— Equity —
Common Stock$38K$17K$17K$17K$17K
Retained Earnings-$58M-$46M-$49M-$52M-$55M
Accumulated OCI$0-$0$0$0$0
Total Stockholders Equity-$4M$8M$5M$2M-$1M
Total Liabilities & Equity$59K$12M$9M$6M$3M
— Key Metrics —
Total Debt$231K$411K$0$0$62K
Net Debt$200K-$12M-$9M-$6M-$2M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms